The FDA has accepted the sNDA for IBTROZI® (taletrectinib), which aims to update the drug’s label with longer-term data in ...
The FDA has granted Fast Track designation to dubodencel (DOC1021) for unresectable or metastatic cutaneous melanoma. The ...
Researchers at MD Anderson have identified RNase H2 as a key survival mechanism in triple-negative breast cancer, helping ...
A pan-cancer analysis of 2,930 patients across 11 tumor types found that ALK mutation was associated with significantly ...
The Zeta Navigation System has received FDA 510(k) clearance alongside the Zeta Stylet and Zeta Bolt, expanding real-time, AI ...
FDA has approved vepdegestrant (VEPPANU), the first PROTAC therapy, for adults with ESR1-mutated ER+/HER2- advanced or ...
A new Cell study suggests that T cell exhaustion in tumors is driven in part by failed proteostasis, causing damaged and misfolded proteins to accumulate inside tumor-infiltrating lymphocytes.
FDA’s advisory committee has endorsed Truqap plus abiraterone and ADT as a treatment option with a favorable benefit-risk ...
Sonire’s first U.S. study of ultrasound-guided, anesthesia-free HIFU ablation therapy has been launched for patients with ...
Phase 2 OPTIMAL-PSMA dosimetry data suggest that TLX597-Tx demonstrated low salivary gland and kidney uptake in metastatic castration-resistant prostate cancer. This favorable profile may support dose ...
AidaBREAST® received FDA Breakthrough Device designation as a multi-omic assay for women with stage I–IIa invasive breast cancer. The test estimates 10-year locoregional recurrence risk and predicts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results